Modified mrna therapeutics
AssigneeShattuck Labs, Inc.
InventorsTaylor SCHREIBER, George FROMM, Casey SHUPTRINE
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to, inter alia, compositions and methods for nucleic acid-based delivery of chimeric proteins that find use in the treatment of a disease or disorder such as selected from cancer, autoimmunity, fibrotic disease, and other inflammatory disorders.
Claims86
A method for treating a cancer, an autoimmune condition, or an inflammatory disorder subject comprising a step of administering to the subject a pharmaceutical composition comprising an isolated polynucleotide encoding a chimeric protein having a general structure of:
- wherein:
- (a) is a first domain comprising an extracellular domain of T cell immunoreceptor with Ig and ITIM domains (TIGIT), or a variant or a fragment thereof that is capable of binding a TIGIT ligand,
- (c) is a second domain comprising an extracellular domain of glucocorticoid-induced TNFR-related protein ligand (GITRL), or a variant or a fragment thereof that is capable of binding a GITRL receptor, or LIGHT (homologous to lymphotoxin, exhibits inducible expression and competes with HSV glycoprotein D for binding to herpesvirus entry mediator, a receptor expressed on T lymphocytes), or a variant or a fragment thereof that is capable of binding a LIGHT receptor,
- (b) is a linker adjoining the first and second domains, wherein the linker comprises at least one cysteine residue capable of forming a disulfide bond and/or comprises a hinge-CH2-CH3 Fc domain.
A method for treating a cancer, an autoimmune condition, or an inflammatory disorder subject comprising a step of administering to the subject a pharmaceutical composition comprising an isolated polynucleotide encoding a chimeric protein having a general structure of:
- wherein:
- (a) is a first domain comprising an extracellular domain of programmed death-1 (PD-1), or a variant or a fragment thereof that capable of binding a PD-1 ligand,
- (c) is a second domain comprising an extracellular domain of OX40 ligand (OX40L), or a variant or a fragment thereof that capable of binding an OX40L receptor, or 4-1BB Ligand (4-1BBL), or a variant or a fragment thereof that capable of binding a 4-1BBL receptor,
- (b) is a linker adjoining the first and second domains, wherein the linker comprises at least one cysteine residue capable of forming a disulfide bond and/or comprises a hinge-CH2-CH3 Fc domain.
A method for treating a cancer, an autoimmune condition, or an inflammatory disorder subject comprising a step of administering to the subject a pharmaceutical composition comprising an isolated polynucleotide encoding a chimeric protein having a general structure of:
- wherein:
- (a) is a first domain comprising an extracellular domain of T-cell immunoglobulin mucin receptor 3 (TIM3), or a variant or a fragment thereof that capable of binding a TIM3 ligand,
- (c) is a second domain comprising an extracellular domain of CD40 ligand (CD40L), or a variant or a fragment thereof that capable of binding a CD40L receptor,
- (b) is a linker adjoining the first and second domains, wherein the linker comprises at least one cysteine residue capable of forming a disulfide bond and/or comprises a hinge-CH2-CH3 Fc domain.
A method for treating a cancer, an autoimmune condition, or an inflammatory disorder subject comprising a step of administering to the subject a pharmaceutical composition comprising an isolated polynucleotide encoding a chimeric protein having a general structure of:
- wherein:
- (a) is a first domain comprising an extracellular domain of V-set and immunoglobulin domain-containing protein 8 (VSIG8), or a variant or a fragment thereof that capable of binding a VSIG8 ligand,
- (c) is a second domain comprising an extracellular domain of 4-1BB Ligand (4-1BBL), or a variant or a fragment thereof that capable of binding a 4-1BBL receptor,
- (b) is a linker adjoining the first and second domains, wherein the linker comprises at least one cysteine residue capable of forming a disulfide bond and/or comprises a hinge-CH2-CH3 Fc domain.
A method for treating a cancer, an autoimmune condition, or an inflammatory disorder subject comprising a step of administering to the subject a pharmaceutical composition comprising an isolated polynucleotide encoding a chimeric protein having a general structure of:
- wherein:
- (a) is a first domain comprising an extracellular domain of signal regulatory protein a (SIRPα), or a variant or a fragment thereof that is capable of binding a SIRPα ligand,
- (c) is a second domain comprising an extracellular domain of CD40 ligand (CD40L), or a variant or a fragment thereof that is capable of binding a CD40L receptor,
- (b) is a linker adjoining the first and second domains, wherein the linker comprises at least one cysteine residue capable of forming a disulfide bond and/or comprises a hinge-CH2-CH3 Fc domain.
A pharmaceutical composition comprising an isolated modified mRNA (mmRNA) encoding a heterologous chimeric protein having an amino acid sequence that has at least about 95% sequence identity with an amino acid sequence selected from SEQ ID NOs:
- 80, 81, and 90-93.
A pharmaceutical composition comprising an isolated modified mRNA (mmRNA) encoding a heterologous chimeric protein having an amino acid sequence that has at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity with an amino acid sequence selected from SEQ ID NOs:
- 80, 81, and 90-93.
Dependencies are inferred from the claim text.